Aegle Therapeutics skips the stem cell transplant and ships only the message the cell was trying to send - a cell-free vesicle therapy now in human trials for one of the cruelest skin diseases in medicine.
PEDRA Technology is a Singapore-based medical device company that built the PEDRA Xauron Perfusion System, the first device to deliver real-time, quantitative measurement of deep-tissue blood perfusion in the foot during vascular procedures. Aimed at physicians treating peripheral arterial disease (PAD) and critical limb threatening ischemia (CLTI), the laser-based, non-invasive system gives interventionalists objective feedback in the angio suite - where they have historically relied on subjective interpretation of X-ray images. The company raised a $4.7M Series A in 2020 and won FDA Breakthrough Device Designation in 2021.
Imagine Pharma is a Pittsburgh biotechnology company built around IMG-1, a novel polypeptide its founder discovered in a tea plant from his native Vietnam. From that single molecule the company runs three platforms - Oral Delivery (making injectable biologics swallowable), Therapeutics, and Regenerative Medicine - with first-in-class programs aimed at curing type 1 diabetes, accelerating diabetic wound healing, and making injections obsolete. Alongside its pipeline, Imagine operates an NIH-approved islet isolation center that has completed dozens of clinical islet cell procedures for major U.S. hospital systems.